Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

Phase 3AnnamycinAnnAraCPositive

AI Analysis

Summary

Moleculin Biotech completed enrollment in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin combination therapy (AnnAraC) for relapsed or refractory AML, with 89 subjects enrolled. The company remains on track for a comprehensive data readout in Q1 2027.

Clinical Trial Data

Phase

Phase 2/3

Patients

Outcome Details

Part A enrollment completed with 89 subjects enrolled

Importance:7/10

Sentiment:

0.60

enrollment completepivotal trialoncologyAMLdata readout expected

Related Companies

$MBRX

Read the original article

Published by GlobeNewswire Pharma on September 29, 2026 12:45 PM

Read Original